Joseph Yozviak
Internal Medicine · Allentown, PANPI 1174561674
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 99.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $12,784 and has fallen 86.0% since, to $1,786 in 2021. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $406.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$27K
- Viiv Healthcare Company$111
- Pfizer$20
- Theratechnologies Inc.$14
Across 133 payments — averaging $8102.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1M
- Merck$41K
- Viiv Healthcare Company$16K
- AbbVie$5K
What the payments were for
- Consulting fees$8,02029%
- Speaking & faculty fees$14,25052%
- Travel & lodging$3,44213%
- Food & beverage$1,4815%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 58 | $27,069 |
| Viiv Healthcare Company | 7 | $111 |
| Pfizer | 1 | $20 |
| Theratechnologies Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$13,830
How this compares
$27,213 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 373 | $1,411,719 |
| TivicayDolutegravir Sodium | 197 | $446,900 |
| EpclusaSofosbuvir/Velpatasvir | 17 | $406,155 |
| DescovyEmtricitabine/Tenofov Alafenam | 144 | $296,003 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 31 | $242,905 |
| DovatoDolutegravir Sodium/Lamivudine | 66 | $172,095 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 47 | $155,353 |
| MavyretGlecaprevir/Pibrentasvir | 12 | $150,637 |
| CabenuvaCabotegravir/Rilpivirine | 22 | $133,317 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $56,661 |
| Dupixent PenDupilumab | 12 | $48,353 |
| JulucaDolutegravir/Rilpivirine | 14 | $47,736 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,475 |
| EliquisApixaban | 29 | $16,108 |
| OzempicSemaglutide | 17 | $15,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Epclusa, Descovy, Genvoya | $27,069 | $2,170,538550 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Cabenuva, Juluca | $111 | $800,048299 claims |
| PfizerEliquis | $20 | $16,10829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Allentown
- Orlando PenalozaAllentown$155K
- Maria JonesAllentown$77K
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.